Denmark-based vaccines company Bavarian Nordic A/S (CPH:BAVA) said on Tuesday that it has agreed a revised contract with the Public Health Agency of Canada (PHAC) to supply doses of IMVAMUNE smallpox/monkeypox vaccine at a value of approximately USD234m plus USD180m in contract options.
This extends the USD56m contract awarded in June 2022 to a total value of up to USD470m.
Bavarian Nordic has also signed a new multi-year contract with Canada's Department of National Defence (DND) at a value of USD2m, in addition to USD18m in contract options.
Under these agreements, the majority of the firm order supply will be delivered in 2023 with the option to procure additional doses annually until 2032 for a total additional value of up to USD198m.
Replicate Bioscience begins phase one trial of RBI-4000 vaccine
Moderna and Immatics form strategic collaboration to develop new oncology therapies
Pfizer and BioNTech's Omicron XBB.1.5-adapted COVID-19 vaccine receives positive CHMP opinion in EU
Valneva's chikungunya vaccine moves forward with Health Canada's review
Allucent Awarded BARDA Contract to Support Acceleration of Next-Generation COVID-19 Booster Vaccines
Anixa Biosciences advances ovarian cancer CAR-T trial with third patient
GC Biopharma signs MoU with GC Biopharma for co-production of Euvichol
GC Biopharma partners with Eubiologics for joint cholera vaccine production
GSK's Shingrix shows 100% efficacy against shingles in Chinese adults
Pfizer's Abrysvo receives FDA approval for pregnant individuals to prevent RSV in infants
Arcturus' mRNA manufacturing partner ARCALIS receives USD115m in grants from the Japanese government
Roquefort Therapeutics boosts patent portfolio with PCT Filing